Case Reports
doi: 10.1002/ajh.10456.
Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory
Affiliations
- PMID: 14755375
- DOI: 10.1002/ajh.10456
Item in Clipboard
Case Reports
Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory
Am J Hematol.
2004 Feb.
Free article
Abstract
A case of a patient with chronic myeloid leukemia whose cells expressed an e13a3 (b2a3) variant BCR-ABL p210 mRNA is presented. The variant splice was detected by a qualitative reverse transcriptase polymerase chain reaction using primers complementary to BCR exon 13 (b2) and ABL exon 3 (a3). The patient responded well to imatinib and achieved a complete cytogenetic response.
Copyright 2004 Wiley-Liss, Inc.
Similar articles
-
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5. doi: 10.1016/j.cancergencyto.2006.11.021. Cancer Genet Cytogenet. 2007. PMID: 17452251
-
[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 15946498 Chinese.
-
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12. Leuk Res. 2010. PMID: 19748671 No abstract available.
-
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.Hematol Oncol. 2006 Dec;24(4):196-204. doi: 10.1002/hon.792. Hematol Oncol. 2006. PMID: 16988930 Review.
-
Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.Blood Rev. 2006 Jan;20(1):29-41. doi: 10.1016/j.blre.2005.01.008. Epub 2005 Mar 2. Blood Rev. 2006. PMID: 16426942 Review.
Cited by
-
CML Chapter.Cancer Treat Res. 2021;181:97-114. doi: 10.1007/978-3-030-78311-2_6. Cancer Treat Res. 2021. PMID: 34626357
-
Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR-ABL1: A report of four cases from India.South Asian J Cancer. 2019 Apr-Jun;8(2):107. doi: 10.4103/sajc.sajc_158_18. South Asian J Cancer. 2019. PMID: 31069190 Free PMC article. No abstract available.
-
Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion.Case Rep Hematol. 2019 Jun 27;2019:9635070. doi: 10.1155/2019/9635070. eCollection 2019. Case Rep Hematol. 2019. PMID: 31346481 Free PMC article.
-
A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy.Oncol Lett. 2018 Feb;15(2):2491-2494. doi: 10.3892/ol.2017.7611. Epub 2017 Dec 13. Oncol Lett. 2018. PMID: 29434963 Free PMC article.
-
A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.Oncol Lett. 2010 Sep;1(5):797-800. doi: 10.3892/ol_00000139. Epub 2010 Sep 1. Oncol Lett. 2010. PMID: 22966382 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
